natgillin/translations-raw huggingface dataset:
In this section, the following categories of frequency have been used: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
U ovom dijelu za prikaz nuspojava prema učestalosti korišteni su sljedeći kriteriji: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
In this section, the following categories of frequency have been used: very common (1/10), common (1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
U ovom dijelu, za prikaz nuspojava prema učestalosti korišteni su sljedeći kriteriji: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
In this section, we call the injection kit the “kit”.
U ovom dijelu komplet za injekciju nazivamo „kompletom“.
In this set of patients, about one quarter were below or at most 6 months of age at diagnosis, and about one third approximately a quarter were between 7 and 36 months.
U ovoj skupini bolesnika, otprilike jedna četvrtina bila je mlađa ili najviše u dobi od 6 mjeseci u trenutku dijagnoze, a otprilike jedna trećina je bila u dobi između 7 i 36 mjeseci.
In this situation, consideration should be given to the need for increased therapy with corticosteroids, e.g. a course of oral corticosteroids, or antibiotic treatment if an infection is present.
U toj situaciji se mora razmotriti potreba za pojačanom terapijom kortikosteroidima, primjerice terapijom oralnim kortikosteroidima, ili liječenjem antibioticima ako je prisutna infekcija.
In this situation, Inflectra should be re-initiated as a single dose followed by the maintenance dose recommendations described above.
U tom slučaju treba započeti terapiju davanjem jedne doze lijeka Inflectra, a zatim nastaviti s dozama održavanja, prema gore opisanim preporukama.
In this situation, Remsima should be re-initiated as a single dose followed by the maintenance dose recommendations described above.
U tom slučaju treba započeti terapiju davanjem jedne doze lijeka Remsima, a zatim nastaviti s dozama održavanja, prema gore opisanim preporukama.
In this small number of adolescents, dabigatran etexilate capsules were apparently tolerated with only three mild and transient gastrointestinal adverse events reported by two patients.
Kod toliko malog broja adolescenata, kapsule dabigatraneteksilata su se očigledno dobro podnosile sa samo tri blage i prolazne gastrointestinalne nuspojave koje su prijavila dva bolesnika.
In this study (n = 281), patients with multiple myeloma received conditioning with melphalan (200 mg/m2) prior to autologous haematopoietic stem cell transplantation.
U sklopu ispitivanja (n = 281) bolesnici s multiplim mijelomom kondicionirani su melfalanom (200 mg/m2) prije autologne transplantacije krvotvornih matičnih stanica.
In this study 100% of animals were protected against homologous challenge, and 81% of animals were protected against heterologous challenge.
U tom je ispitivanju 100% životinja bilo zaštićeno od homolognog virusa, a 81% životinja bilo je zaštićeno od heterolognog virusa.
In this study 150 patients with NYHA Class III-IV CHF (left ventricular ejection fraction ≤ 35%) were treated with 3 infusions of infliximab 5 mg/kg, 10 mg/kg, or placebo over 6 weeks.
U tom je ispitivanju 150 bolesnika s kroničnim zatajenjem srca NYHA stupnja III-IV (ejekcijska frakcija lijeve klijetke ≤ 35%) liječeno s 3 infuzije infliksimaba u dozi od 5 mg/kg odnosno 10 mg/kg ili placebom tijekom 6 tjedana.
In this study 150 patients with NYHA Class III-IV CHF (left ventricular ejection fraction ≤ 35%) were treated with 3 infusions of Remicade 5 mg/kg, 10 mg/kg, or placebo over 6 weeks.
U tom je ispitivanju 150 bolesnika s kroničnim zatajenjem srca NYHA stupnja III-IV (ejekcijska frakcija lijeve klijetke ≤ 35%) liječeno sa 3 infuzije lijeka Remicade u dozi od 5 mg/kg odnosno 10 mg/kg ili placebom tijekom 6 tjedana.
In this study 150 patients with NYHA Class III-IV CHF (left ventricular ejection fraction ≤35%) were treated with 3 infusions of infliximab 5 mg/kg, 10 mg/kg, or placebo over 6 weeks.
U tom je ispitivanju 150 bolesnika s kroničnim zatajenjem srca NYHA stupnja III-IV (ejekcijska frakcija lijeve klijetke ≤ 35%) liječeno sa 3 infuzije lijeka infliksimab u dozi od 5 mg/kg odnosno 10 mg/kg ili placebom tijekom 6 tjedana.
In this study 150 patients with NYHA Class III-IV CHF (left ventricular ejection fraction ≤35%) were treated with 3 infusions of infliximab 5 mg/kg, 10 mg/kg, or placebo over 6 weeks.
U tom je ispitivanju 150 bolesnika s kroničnim zatajenjem srca NYHA stupnja III-IV (ejekcijska frakcija lijeve klijetke ≤ 35%) liječeno sa 3- infuzije lijeka infliksimab u dozi od 5 mg/kg odnosno 10 mg/kg ili placebom tijekom 6 tjedana.
In this study 277 patients were randomised in a 2:2:1 ratio to the following arms:
U ovom ispitivanju bilo je randomizirano 277 bolesnika u omjeru 2:2:1 u jednu od sljedećih skupina:
In this study 277 patients were randomised in a 2:2:1 ratio to the following arms:
U ovom ispitivanju bilo je randomizirano 277 bolesnika u omjeru 2:2:1 u jednuod sljedećih skupina:
In this study 85% (64 out of 75) patients treated with RoActemra responded to treatment and no longer had fever after three months, compared with 24% (9 out of 37) patients receiving placebo.
U tom ispitivanju 85 % (64 od 75) bolesnika liječenih lijekom RoActemra odgovorilo je na terapiju i više nisu imali vrućicu nakon tri mjeseca, u usporedbi s 24 % (9 od 37) bolesnika koji su primili placebo.
In this study a specific subgroup of patients who had symptomatic angina had a small but significant increase in the combined risk of cardiovascular death or non-fatal heart attack with Ivabradine Anpharm compared with placebo (3.4% vs 2.9% yearly incidence rates).
U ovom ispitivanju, određena podgrupa bolesnika koja je imala simptomatičnu anginu imala je malo no značajno povećanje u kombiniranom riziku kardiovaskularne smrti i srčanog zastoja bez smrtonosnog ishoda s lijekom Ivabradine Anpharm u usporedbi s placebom (3,4% u odnosu na 2,9% godišnji stopa incidencije).
In this study Imbruvica was not compared with any other treatment.
U ovom ispitivanju lijek Imbruvica nije uspoređen niti s jednom drugom terapijom.
In this study in male patients with LUTS/BOO, the adjusted mean (SE) change from baseline to end of treatment in post void residual volume (mL) was 0.55 (10.702), 17.89 (10.190), 30.77 (10.598) for the placebo, mirabegron 50 mg and mirabegron 100 mg treatment groups.
U ovom ispitivanju na muškim bolesnicima sa simptomima donjeg urinarnog trakta/opstrukcije na izlazu iz mjehura, prilagoĎena srednja (SE) vrijednost razlike rezidualnog volumena (ml) nakon mokrenja, od polaznih vrijednosti do vrijednosti na kraju liječenja, iznosila je 0,55 (10,702), 17,89 (10,190) odnosno 30,77 (10,598) za placebo skupinu, odnosno mirabegron 50 mg i mirabegron 100 mg liječenih skupina.
In this study in patients receiving pioglitazone and insulin, a higher percentage of patients with heart failure was observed in patients aged ≥ 65 years compared with those less than 65 years (9.7% compared to 4.0%).
U ovom ispitivanju, u bolesnika koji su primali pioglitazon i inzulin zabilježen je veći postotak bolesnika sa zatajenjem srca u skupini bolesnika u dobi od ≥65 godina u odnosu na one mlađe od 65 godina (9,7% u odnosu na 4,0%).
In this study Mekinist was more effective than dacarbazine or paclitaxel in controlling the disease: patients taking Mekinist lived on average for 4.8 months without their disease getting worse, compared with 1.5 months for patients given dacarbazine or paclitaxel.
U tom ispitivanju lijek Mekinist pokazao se djelotvornijim od dakarbazina ili paklitaksela u kontroliranju bolesti: bolesnici koji su uzimali Mekinist živjeli su prosječno 4,8 mjeseci bez pogoršanja bolesti, u odnosu na 1,5 mjeseci u slučaju bolesnika koji su uzimali dakarbazin ili paklitaksel.
In this study most psoriatic arthritis patients receiving Enbrel were able to mount effective B-cell immune response to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and few patients had two-fold rises in titers compared to patients not receiving Enbrel.
U ovom ispitivanju je većina bolesnika s psorijatičnim artritisom koji su primali Enbrel mogla postići učinkovit imunološki odgovor B-stanica na pneumokokno polisaharidno cjepivo, iako su vrijednosti titra u agregatu bile umjereno niže, dok je nekoliko bolesnika imalo dvostruki porast titra u usporedbi s bolesnicima koji nisu primali Enbrel.
In this study the age range of patients was 65-75 years, with 41% (183/447) of patients 70 years old or older.
U ispitivanju je raspon dobi bolesnika iznosio 65-75 godina s 41% (183/447) bolesnika u dobi od 70 godina i starijih.
In this study the frequency of hyponatraemia in the ranolazine group was rare.
U ovom ispitivanju je učestalost hiponatremije u skupini na ranolazinu bila rijetka.
In this study the objective response rate was 36.5% (95% CI: 24.7% - 49.6%) and the median time to progression (TTP) was 37.7 weeks (95% CI: 24.0 - 46.4 weeks).
U ovom je ispitivanju stopa objektivnog odgovora bila 36,5% (95% CI: 24,7%-49,6%), a medijan vremena do progresije bolesti (TTP) 37,7 tjedana (95% CI: 24,0-46,4 tjedna).
In this study the ORR was 35.8% (95% CI: 26.8% – 47.5 %).
U ovom je ispitivanju ORR iznosio 35,8% (95% CI: 26,8%-47,5%).
In this study the safety profile in adolescent patients was similar to that in adults (see section 5.1).
Sigurnosni profil u adolescentnih bolesnika u ovom ispitivanju bio je sličan onome u odraslih (vidjeti dio 5.1).
In this study there was an increased incidence of hospitalisation due to CHF during the first 4–8 weeks of treatment with bosentan, which could have been the result of fluid retention.
U toj studiji učestalost hospitalizacije zbog kroničnog zatajenja srca tijekom prvih 4–8 tjedana liječenja bosentanom bila je povećana, što je možda bio rezultat zadržavanja tekućine.
In this study, 10 patients experienced elevations in AST and/or ALT >3 x ULN (see Table 6).
U ovom ispitivanju u 10 bolesnika došlo je do povišenja AST i/ili ALT > 3 x GGN (vidjeti Tablica 6).
In this study, 14 patients with HES/CEL were treated with 100 mg to 1,000 mg of imatinib daily.
U tom ispitivanju, 14 bolesnika s HES/KEL-om je liječeno imatinibom od 100 mg do 1000 mg na dan.
In this study, 14 patients with HES/CEL were treated with 100 mg to 1,000 mg of imatinib daily.
U tom kliničkom ispitivanju, 14 bolesnika s HES/KEL- om je liječeno imatinibom u dozi od 100 mg do 1000 mg na dan.
In this study, 14patients with HES/CEL were treated with 100 mg to 1,000 mg of imatinib daily.
U tom kliničkom ispitivanju, 14 bolesnika s HES/KEL-om je liječeno imatinibom od 100 mg do 1000 mg na dan.
In this study, 2 patients treated with Epclusa for 12 or 24 weeks without ribavirin had emergent NS5B S282T at low levels (< 5%) along with L159F.
U ovom su ispitivanju dva bolesnika liječenja lijekom Epclusa tijekom 12 ili 24 tjedna bez ribavirina imala pojavu NS5B S282T pri niskim razinama (< 5 %) uz L159F.
In this study, 255 patients were randomised to treatment with docetaxel (75 mg/m² as a 1 hour intravenous infusion every weeks) and capecitabine (1250 mg/m² twice daily for 2 weeks followed by 1-week rest period).
U ovoj studiji randomizirano je 255 bolesnika za liječenje docetakselom (75 mg/m2 u obliku jednosatne intravenske infuzije svaka 3 tjedna) i kapecitabinom (1250 mg/m2 dvaput dnevno tijekom 2 tjedna nakon čega slijedi jedan tjedan pauze).
In this study, 29.1% of the patients had an inadequate initial response (primary non-responders), 69.4% responded but lost response (secondary non-responders), and 36.4% were intolerant to anti- TNFα therapies.
U ovom ispitivanju, 29,1% bolesnika imalo je neadekvatan inicijalni odgovor (primarno nisu odgovorili), 69,4% ih je odgovorilo ali su izgublili odgovor (sekundarno nisu odgovorili), a 36,4% ih nije podnosilo anti-TNFα terapiju.
In this study, 358 patients with inoperable locally advanced SCCHN, and WHO perfomance status 0 or 1, were randomized to one of two treatment arms.
U ovoj je studiji 358 bolesnika s inoperabilnim, lokalno uznapredovalim SCCHN, WHO izvedbenog statusa 0 ili 1, bilo randomizirano u jednu od dvije liječene skupine.
In this study, 501 patients, with locally advanced SCCHN, and a WHO performance status of 0 or 1, were randomized to one of two arms.
U ovom je ispitivanju u dvije skupine bio randomiziran 501 bolesnik s lokalno uznapredovalim SCCHN, WHO izvedbenog statusa 0 ili 1.
In this study, 501 patients, with locally advanced SCCHN, and a WHO performance status of 0 or 1, were randomized to one of two arms.
U ovom je ispitivanju u dvije skupine bio randomiziran 501 bolesnik s lokalno uznapredovalimSCCHN, WHO izvedbenog statusa 0 ili 1.
In this study, 501 patients, with locally advanced SCCHN, and a WHO performance status of 0 or 1, were randomized to one of two arms.
U ovom je ispitivanju, u dvije skupine bio randomiziran 501 bolesnik s lokalno uznapredovalim SCCHN, funkcionalnog statusa 0 ili 1 prema SZO ljestvici.
In this study, 7 patients with moderate renal impairment were treated with 20 mg/m2 Teysuno twice daily, while 7 patients with severe renal impairment received Teysuno 20 mg/m2 once daily.
U toj studiji je 7 bolesnika sa umjerenim oštećenjem bubrega primalo 20 mg/m2 lijeka Teysuno dva puta dnevno, dok je 7 bolesnika sa teškim oštećenjem bubrega primalo 20 mg/m2 lijeka Teysuno jedanput na dan.
In this study, 91% (296 out of 327) of patients tested negative for hepatitis C 12 weeks after the end of treatment.
U tom je ispitivanju 91 % bolesnika (296 od 327) bilo negativno prilikom testiranja na hepatitis C 12 tjedana nakon završetka terapije.
In this study, a durable protection was statistically demonstrated to approximately 8 years.
U ovom je ispitivanju statistički dokazana zaštita u trajanju od približno 8 godina.
In this study, a durable protection was statistically demonstrated to approximately 8 years.
U tom je ispitivanju statistički pokazano da zaštita traje približno 8 godina.
In this study, a modification of the Zevalin therapeutic regimen with a lower [90Y]-Zevalin activity per body weight (11 MBq/kg) was used.
U ovom ispitivanju koristio se modificirani terapijski protokol Zevalina s manjom aktivnošću [90Y]-Zevalina po tjelesnoj težini (11 MBq/kg).
In this study, adding Empliciti to the two other medicines extended the average time before the disease got worse from 14.3 months to 18.5 months.
U tom je ispitivanju dodavanje lijeka Empliciti drugim dvama lijekovima produljilo prosječno vrijeme u kojem se bolest nije pogoršala s 14,3 na 18,5 mjeseci.
In this study, administration of the chewable tablet with a high fat meal led to an average 6 % decrease in AUC, 62 % decrease in Cmax, and 188 % increase in C12hr compared to administration in the fasted state.
U ovom je ispitivanju nakon primjene tablete za žvakanje, uz punomastan obrok, dovela do smanjenja AUC-a za 6%, a Cmax je smanjen za 62%, dok je C12h bio 188% veći u usporedbi s primjenom natašte.
In this study, all patients also received methotrexate and the main measure of effectiveness was the number of patients who achieved sustained remission (no detectable disease activity) after 52 weeks of treatment.
U tom ispitivanju svi su bolesnici također primili metotreksat, a glavna mjera djelotvornosti bio je broj bolesnika u kojih je zabilježena trajna remisija (nije zamijećena progresija bolesti) nakon 52 tjedna liječenja.
In this study, AT arm showed a higher incidence of severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3% versus 10%), infection (8% versus 2.4%), diarrhoea (7.5% versus 1.4%), asthenia (8.5% versus 2.4%), and pain (2.8% versus 0%) than AC arm.
U ovom je ispitivanju AT skupina u odnosu na AC skupinu pokazala veću incidenciju teške neutropenije (90% prema 68,6%), febrilne neutropenije (33,3.% prema 10%), infekcije (8% prema
In this study, Blincyto was not compared with any other treatment.
U ovom ispitivanju lijek Blincyto nije uspoređen niti s jednom drugom terapijom.
In this study, exercise duration was longest in the 1500 mg group; however, there was a disproportional increase in side effects, and the 1500 mg dose was not studied further.
U ovom istraživanju trajanje opterećenja bilo je najdulje kod skupine koja je primala 1500 mg; međutim, postojalo je neproporcionalno povećanje učestalosti nuspojava, tako da korištenje doze od 1500 mg nije dalje ispitivano.
In this study, Exjade was compared with placebo (a dummy treatment) and the main measure of effectiveness was the change in iron levels in the liver after 12 months of treatment.
U tom je ispitivanju lijek Exjade uspoređivan s placebom (prividnim liječenjem), a glavna mjera djelotvornosti bila je promjena razina željeza u jetri nakon 12 mjeseci liječenja.
In this study, Exviera and ombitasvir/paritaprevir/ritonavir without ribavirin had a similar SVR12 rate (100%) compared to Exviera and ombitasvir/paritaprevir/ritonavir with ribavirin (97.7%).
U tom su ispitivanju stope SVR12 uz primjenu lijekova Exviera i ombitasvir/paritaprevir/ritonavir bez ribavirina (100%) bile slične onima postignutima uz primjenu lijekova Exviera i ombitasvir/paritaprevir/ritonavir u kombinaciji s ribavirinom (99,5%).
In this study, forty-six (43 %) patients received G-CSF over 192 (42.1 %) courses; sixty-five (60 %) received transfusions of Packed Red Blood Cells and fifty (46 %) of platelets over 139 and 159 courses (30.5 % and 34.9 %) respectively.
U ovom je ispitivanju 46 bolesnika (43%) nakon 192 (42,1%) ciklusa primilo filgrastim (G-CSF); 65 bolesnika (60%) je nakon 139 (30,5%) ciklusa primilo transfuziju eritrocita, a 50 njih (46%) nakon 159 (34,9%) ciklusa transfuziju trombocita.
In this study, forty-six (43 %) patients received G-CSF over 192 (42.1 %) courses; sixty-five (60 %) received transfusions of Packed Red Blood Cells and fifty (46 %) of platelets over 139 and 159 courses (30.5 % and 34.9 %) respectively.
U ovom je ispitivanju 46 bolesnika (43%) tijekom 192 (42,1%) ciklusa primilo G-CSF; 65 bolesnika (60%) je tijekom 139 (30,5 %) ciklusa primilo transfuziju koncentrata eritrocita, a 50 njih (46%) tijekom 159 (34,9%) ciklusa transfuziju trombocita.
In this study, forty-six (43 %) patients received G-CSF over 192 (42.1 %) courses; sixty-five (60 %) received transfusions of Packed Red Blood Cells and fifty (46 %) of platelets over 139 and 159 courses (30.5 % and 34.9 %) respectively.
U ovom je ispitivanju 46 bolesnika (43%) tijekom 192 (42,1%) ciklusa primilo G-CSF; 65 bolesnika (60%) je tijekom 139 (30,5%) ciklusa primilo transfuziju eritrocita, a 50 njih (46%) tijekom 159 (34,9%) ciklusa transfuziju trombocita.
In this study, forty-six (43%) patients received G-CSF over 192 (42.1%) courses; sixty-five (60%) received transfusions of Packed Red Blood Cells and fifty (46%) of platelets over 139 and 159 courses (30.5% and 34.9%) respectively.
U ovom je ispitivanju 46 bolesnika (43%) nakon 192 (42,1%) ciklusa primilo G-CSF; 65 bolesnika (60%) je nakon 139 (30,5 %) ciklusa primilo transfuziju eritrocita, a 50 njih (46%) nakon 159 (34,9%) ciklusa transfuziju trombocita.
In this study, Galafold was found to be as effective as enzyme replacement in stabilising patients’ kidney function.
U tom je ispitivanju zaključeno da je Galafold jednako učinkovit kao nadomještanje enzima pri stabiliziranju funkcije bubrega u bolesnika.
In this study, Intelence was not compared with another treatment and the children also took at least two other anti-HIV medicines.
U ovom ispitivanju, Intelence nije uspoređen s drugim liječenjem, a djeca su također uzimala najmanje dva druga lijeka protiv HIV-a.
In this study, neither superiority nor non-inferiority to placebo + OBT were demonstrated although there was no adverse outcome on viral load or CD4+ cell count.
U ovom ispitivanju nije utvrđena ni superiornost niti ne-inferiornost u odnosu na liječenje kombinacijim placebo + OBT, iako nije bilo neželjenog ishoda vezanih uz brojnost virusa odnosno broj CD4+ stanica.
In this study, neither superiority nor non-inferiority to placebo + OBT were demonstrated although there was no adverse outcome on viral load or CD4+ cell count.
U ovom ispitivanju nije utvrđena ni superiornost niti ne-inferiornost u odnosu na liječenje kombinacijom placebo + OBT, iako nije bilo neželjenog ishoda vezanih uz brojnost virusa odnosno broj CD4+ stanica.
In this study, only chemotherapy-naive subjects, not receiving additional chemotherapy after surgery, were treated with low cumulative dose of epirubicin, i.e. up to 300 mg/m2.
U tom su ispitivanju samo ispitanice koje prethodno nisu bile liječene kemoterapijom i koje nisu primale dodatnu kemoterapiju nakon operacije bile liječene niskom kumulativnom dozom epirubicina, do 300 mg/m2.
In this study, patients given Sovaldi together with ribavirin for 12 weeks were compared with patients given peginterferon alfa and ribavirin for 16 weeks.
U tom su ispitivanju bolesnici koji su primali Sovaldi s ribavirinom tijekom 12 tjedana uspoređeni s bolesnicima koji su primali peginterferon alfa i ribavirin tijekom 16 tjedana.
In this study, patients on 1 or 2 insulin injections per day prior to study entry, discontinued their prestudy insulin regimen and were randomised to dulaglutide once weekly or insulin glargine once daily, both in combination with prandial insulin lispro three times daily, with or without metformin.
U ovom su ispitivanju bolesnici koji su prije uključivanja u ispitivanje primjenjivali 1 ili 2 injekcije inzulina na dan prekinuli dotadašnji režim liječenja inzulinom te su randomizirani na primanje dulaglutid jedanput na tjedan ili inzulin glargin jedanput na dan, oba u kombinaciji s prandijalnim inzulinom lispro triput na dan, uz metformin ili bez njega.
In this study, patients received Revestive or placebo (a dummy treatment) every day for 24 weeks.
U tom su ispitivanju bolesnici primali Revestive ili placebo (slijepo liječenje) svaki dan tijekom 24 tjedna.
In this study, patients treated with alirocumab who developed ADA had a lower incidence of injection site reactions compared with patients who did not develop ADA (8.6% vs 16.2%).
U ovom su ispitivanju bolesnici liječeni alirokumabom, koji su razvili protutijela na lijek, imali manju incidenciju reakcija na mjestu injiciranja u usporedbi s bolesnicima koji nisu razvili protutijela na lijek (8,6% naspram 16,2%).
In this study, patients were prescribed 20 mg /kg, 25 mg /kg, 40 mg /kg or 50 mg /kg daily dose of oral solution based on their age titration schedule.
U toj je studiji bolesnicima propisana oralna otopina u dnevnoj dozi od 20 mg/kg,
In this study, slow acetylators experienced more adverse reactions than the fast acetylators.
U ovom ispitivanju spori acetilatori imali su više nuspojava od brzih acetilatora.
In this study, structural joint damage was assessed radiographically and expressed as change in Total Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score.
U ovom ispitivanju strukturalno oštećenje zglobova procijenjeno je radiografski te prikazano kao promjena ocjene na Sharpovoj ljestvici (Total Sharp Score – TSS) i njenim dijelovima, ocjene erozije i ocjena suženja zglobnog prostora (Joint Space Narrowing score – JSN).
In this study, the adverse events reported were similar to those seen in previous studies in adults with plaque psoriasis.
U ovom ispitivanju, prijavljene nuspojave bile su slične onima zabilježenim u prethodnim ispitivanjima kod odraslih bolesnika s plak psorijazom.